Of twelve patients receiving BPC-157 alone as an intra-articular injection, eleven reported meaningful pain improvement a 92% response rate
Figure 1: Changes in body weight from baseline to the end of treatment at week 26 associated with the trial product estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
2) Pro-angiogenic Signaling via VEGFR2 Akt eNOS In cellular and animal models, BPC-157 increased endothelial tube formation and improved blood-flow recovery after hind-limb ischemia
Enhance overall gut function, thereby improving nutrient absorption and reducing symptoms associated with gluten sensitivity and autoimmune conditions
The gradual escalation lets the GI tract adapt and dramatically improves tolerability